BriaCell Therapeutics (BCTXF) Stock Price, News & Analysis

Company Overview

BriaCell Therapeutics Corp. operates as a clinical-stage biotechnology company that specializes in immunotherapy for advanced breast cancer. It is advancing its targeted immunotherapy program by conducting a Phase I/IIA clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor and a companion diagnostic test, BriaDx, to identify patients to benefit from Bria-IMT. The company was founded by Charles L. Wiseman and Isaac B. Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.

Key Stats

• Today's Range: $0.72 to $0.81
• 50-Day Range: $0.75 to $3.53
• 52-Week Range: $3.25 to $17.50
• Volume: 1.69 million shs
• Average Volume: 1,859 shs
• Market Capitalization: $575.60 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BCTXF Stock Analysis - Frequently Asked Questions

How have BCTXF shares performed this year?

BriaCell Therapeutics' stock was trading at $0.5558 at the beginning of 2025. Since then, BCTXF shares have increased by 34.1% and is now trading at $0.7456.

How do I buy shares of BriaCell Therapeutics?

Shares of BCTXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:BCTXF
• CIK: N/A
• Web: www.briacell.com
• Phone: (604) 921-1810
• Fax: N/A
• Employees: 8
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($3.84)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3.68 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -786.77%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.07
• Quick Ratio: 0.07

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($4.55) per share
• Price / Book: -0.16

Miscellaneous

• Outstanding Shares: 772,000
• Free Float: N/A
• Market Cap: $575.60 thousand
• Optionable: Not Optionable
• Beta: 1.09